S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:KERN

Akerna (KERN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.31
$9.80
52-Week Range
N/A
Volume
70,795 shs
Average Volume
339,022 shs
Market Capitalization
$64.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KERN stock logo

About Akerna Stock (NASDAQ:KERN)

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

KERN Stock News Headlines

Akerna Corp. Simplifies Stock Structure, Alters Fiscal Year
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Gryphon Digital Mining, Inc. Debuts on Nasdaq
Gryphon Digital Mining Debuts on Nasdaq
Akerna Corp Ordinary Shares
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Akerna Corp. Wt
Why Akerna Stock Is Exploding Higher Today
Akerna (NASDAQ: KERN)
Akerna to Sell its Cannabis Software Business
See More Headlines
Receive KERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akerna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2021
Today
4/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Nondepository credit institutions
Sub-Industry
N/A
Current Symbol
NASDAQ:KERN
Fax
N/A
Employees
112
Year Founded
N/A

Profitability

Net Income
$-79,060,000.00
Net Margins
-339.99%
Pretax Margin
-208.10%

Debt

Sales & Book Value

Annual Sales
$13.65 million
Book Value
($1.52) per share

Miscellaneous

Free Float
10,228,000
Market Cap
$64.92 million
Optionable
No Data
Beta
3.02
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Jessica Billingsley (Age 47)
    Founder, CEO & Chairman of the Board
    Comp: $462.3k
  • Mr. Larry Dean Ditto Jr. (Age 57)
    Chief Financial Officer
    Comp: $177.71k
  • Mr. David R. McCullough (Age 47)
    Chief Technology Officer
    Comp: $240.43k
  • Georgia Jablon
    Communications Manager

KERN Stock Analysis - Frequently Asked Questions

How were Akerna's earnings last quarter?

Akerna Corp. (NASDAQ:KERN) issued its earnings results on Sunday, November, 7th. The company reported ($2.80) earnings per share for the quarter, beating analysts' consensus estimates of ($3.00) by $0.20. The business earned $5.14 million during the quarter, compared to analyst estimates of $5.11 million. During the same period in the prior year, the business posted ($6.80) EPS.

When did Akerna's stock split?

Shares of Akerna reverse split on the morning of Friday, February 9th 2024. The 1-20 reverse split was announced on Friday, February 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akerna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akerna investors own include KushCo (KSHB), Organigram (OGI), Supreme Cannabis (SPRWF), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Medical Marijuana (MJNA), MariMed (MRMD), Matinas BioPharma (MTNB), CNBX Pharmaceuticals (CNBX) and DHT (DHT).

This page (NASDAQ:KERN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners